The Effect of Dexmedetomidine on Microcirculation in Severe Sepsis

Status Terminated

Clinical Trial Summary

Despite early goal-directed maintenance of normal macrocirculation, the reduction of 60-day mortality of patients with severe sepsis and septic shock remained unsatisfied (56.9% to 44.3%). One of the major causes of high mortality is microcirculatory dysfunction. Delayed diagnosis and treatment of microcirculatory dysfunction may cause tissue hypoperfusion and resulted in multiple organ dysfunction and death. Dexmedetomidine is a highly selective α2-adrenoreceptor agonist which exhibits sedative and analgesic effects. Recent studies suggest that dexmedetomidine also has anti-coagulation and anti-inflammatory effects, and it can reduce the mortality of endotoxemic rats and patients with severe sepsis. The investigators will conduct two animal studies and one clinical trial to investigate the effect of dexmedetomidine on microcirculatory dysfunction and organ injury in rat with endotoxemia and patients with severe sepsis and septic shock.

Sixty patients with severe sepsis and septic shock will be enrolled and randomized to control group or dexmedetomidine group. In the control group, the patients will be treated according to the clinical practice guideline. If sedation is required, non-dexmedetomidine sedative agents will be used. In the dexmedetomidine group, the patients will be treated according to the clinical practice guideline, and they will also receive continuous infusion of dexmedetomidine (infusion rate ranged from 0.1 to 0.7 mcg/kg/h) for 24 hours as needed. The sublingual microcirculation, serum level of Endocan, NGAL(Neutrophil Gelatinase-Associated Lipocalin), and BNP(B-type natriuretic peptide) will be examined at preset time points up to 24 hours. The vital signs, hemodynamic parameters, and survival of 28-day and 90-day will be recorded and analyzed.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02109965
Study type	Interventional
Source	National Taiwan University Hospital
Contact
Status	Terminated
Phase	Phase 4
Start date	July 2014
Completion date	February 24, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04804306` - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Completed	`NCT04227652` - Control of Fever in Septic Patients	N/A
Recruiting	`NCT04005001` - Machine Learning Sepsis Alert Notification Using Clinical Data	Phase 2
Recruiting	`NCT02899143` - Short-course Antimicrobial Therapy in Sepsis	Phase 2
Completed	`NCT02539147` - Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis	N/A
Completed	`NCT01932814` - Acute Kidney Injury in Septic Critically Ill Patients : Are Aminoglycosides Really Harmful?	N/A
Completed	`NCT01929772` - German Lactat Clearance in Severe Sepsis	N/A
Completed	`NCT01449721` - Preemptive Resuscitation for Eradication of Septic Shock	N/A
Active, not recruiting	`NCT01162109` - Zinc Therapy in Critical Illness	Phase 1
Not yet recruiting	`NCT01211899` - 4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock	N/A
Completed	`NCT00934011` - Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections	N/A
Recruiting	`NCT00335907` - Protocol-driven Hemodynamic Support for Patients With Septic Shock	N/A
Completed	`NCT00463645` - Investigation of Correlation Between Interstitial and Arterial Blood Glucose Concentrations in Septic Patients	N/A
Completed	`NCT02361528` - GM-CSF to Decrease ICU Acquired Infections	Phase 3
Completed	`NCT02734550` - (1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection in Sepsis	N/A
Completed	`NCT02973243` - The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III	N/A
Terminated	`NCT03895853` - Early Metabolic Resuscitation for Septic Shock	Phase 2
Completed	`NCT01945983` - Early Use of Norepinephrine in Septic Shock Resuscitation	N/A
Completed	`NCT01598831` - Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy	Phase 3
Enrolling by invitation	`NCT02258984` - Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial	N/A